menu
    • menu
    [{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Sitravatinib","moa":"TYRO3","graph1":"Oncology","graph2":"Phase II","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mirati Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mirati Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Sitravatinib","moa":"TYRO3","graph1":"Oncology","graph2":"Phase III","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mirati Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mirati Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Sitravatinib","moa":"TYRO3","graph1":"Oncology","graph2":"Phase II","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mirati Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mirati Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Mirati Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Tislelizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Mirati Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ Mirati Therapeutics"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sitravatinib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mirati Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mirati Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sitravatinib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mirati Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mirati Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Sitravatinib

    Menu

    Sitravatinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Mirati Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Mirati Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sitravatinib,Nivolumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Mirati Therapeutics Provides Update on the Phase 3 SAPPHIRE Study Evaluating Sitravatinib in Combination with ...

                            Details : MGCD516 (sitravatinib) is an investigational spectrum-selective kinase inhibitor that potently inhibits receptor tyrosine kinases (RTKs), including TAM family receptors (TYRO3, Axl, Mer), split family receptors (VEGFR2, KIT) and RET.

                            Brand Name : MGCD516

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 24, 2023

                            Lead Product(s) : Sitravatinib,Nivolumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Mirati Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Mirati Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sitravatinib,Nivolumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Mirati Therapeutics Announces Update for the Phase 3 SAPPHIRE Study

                            Details : MGCD516 (sitravatinib) is an investigational spectrum-selective kinase inhibitor that potently inhibits receptor tyrosine kinases (RTKs), including TAM family receptors (TYRO3, Axl, Mer), split family receptors (VEGFR2, KIT) and RET.

                            Brand Name : MGCD516

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 02, 2022

                            Lead Product(s) : Sitravatinib,Nivolumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            BeiGene

                            China arrow
                            Antibody Engineering
                            Not Confirmed

                            BeiGene

                            China arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tislelizumab,Sitravatinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Mirati Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BeiGene to Present Latest Findings in Robust Lung Cancer Portfolio at ESMO Congress 2021

                            Details : BeiGene is pursuing diverse mechanisms of action in combination with tislelizumab to complement targeting of the PD-1 pathway for potentially improved clinical outcomes or to overcome resistance associated with disease progression.

                            Brand Name : BGB-A317

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 12, 2021

                            Lead Product(s) : Tislelizumab,Sitravatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Mirati Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Mirati Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Mirati Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sitravatinib,Nivolumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Mirati Therapeutics Presents Phase 2 Data On Sitravatinib In Combination With Nivolumab In Urothelial Cancer A...

                            Details : The combination of sitravatinib with nivolumab demonstrated promising clinical activity in checkpoint inhibitor-naïve, platinum-refractory patients.

                            Brand Name : MGCD516

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 18, 2020

                            Lead Product(s) : Sitravatinib,Nivolumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Mirati Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Mirati Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sitravatinib,Nivolumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Mirati Therapeutics Appoints Joseph A. Leveque, M.D. As Chief Medical Officer

                            Details : Joseph A. Leveque will assist Mirati to further advance its registration-enabling clinical trials for both sitravatinib and MRTX849, as well as advance its preclinical pipeline including the KRAS G12D inhibitor program.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 18, 2020

                            Lead Product(s) : Sitravatinib,Nivolumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Mirati Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Mirati Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sitravatinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Mirati Therapeutics Reveals Data In Renal Cell Carcinoma From an Ongoing Trial Of Sitravatinib In Combination ...

                            Details : Mirati Therapeutics is conducting ongoing investigator sponsored Phase 1/2 clinical trial of sitravatinib in combination with nivolumab in patients.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 15, 2020

                            Lead Product(s) : Sitravatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth